Dr. Bunce has over 19 years’ experience working in the biotech and diagnostics sectors, occupying senior management positions within Piramed Pharma (Director, Development Programmes), Immune Targeting Systems (R & D Director) and Oxford Immunotec (General Manager, Immunology Products). He has extensive experience in developing novel biologics and vaccines for cancer, inflammatory and infectious diseases, leading them through development and regulatory processes including pre-clinical evaluation and translation in the clinic.

Campbell has a PhD in Immunology from the University of Manchester and has published a number of papers in T cell biology, immunomodulators and vaccines.

Louise is responsible for providing technical and CMC regulatory leadership and guidance across the Abzena portfolio from Early Development to Commercial production. She is responsible for ensuring scientific input is provided to project teams and works collaboratively with clients for project success. Louise serves as a principle point for contact for clients.

Louise has a very extensive background in the global Bio/pharmaceutical industry with more than 30 years of experience in R&D and Commercial Supply having held senior roles in GlaxoSmithKline as VP & Global Supply Chain Head, Biopharmaceuticals and Janssen R&D (J&J) as VP & Global Head, Strategic Sciences. She has wide-ranging experience in developing, licensing, and supplying Biopharmaceuticals, Vaccines, Cell and Gene Therapy products for global markets. Louise joined Abzena in 2020 as SVP & Head of Scientific Project Leaders

Louise expertise is in the development, technology transfer, and supply of biopharmaceuticals, vaccines, and cell & gene therapies. She has in-depth CMC and Regulatory experience including the development of strategic CMC plans to support regulatory filings such as INDs, IMPDs, BLA, MAAs